Rumours, Manipulating In Addition To The PCI-32765

Матеріал з HistoryPedia
Перейти до: навігація, пошук

Models were repeated with use of neuroleptics and hypnotics. A separate model was used for anticholinesterate inhibitors (MMSE was included as independent Thalidomide variable while BDI and depression diagnosis were dropped). One hundred patients were initially included in the study and 92 were retained due to missing insurance data. Patients not insured were younger (median 59 vs. 70 years, P Selleck PARP inhibitor patients were not receiving hypnotics. A logistic regression model indicated that patients without insurance had 7.12 (95% confidence interval 1.88�C26.86) higher odds of not being prescribed an antidepressant compared to patients with insurance (Table 2 in Supplemental Material found at: doi:10.1016/j.jval.2011.05.014). No other point estimate reached statistical significance. Increasing age and more comorbidities were associated with higher odds of not receiving treatment whereas more years of schooling, diagnosis other than subsyndromal depression, and higher BDI were associated with lower odds of not receiving treatment. No health care insurance was also associated with higher odds of not being prescribed neuroleptics or hypnotics and with lower odds of being prescribed anticholinesterase inhibitors, although the results were not statistically significant. Older age was associated with higher odds of not being prescribed hypnotics and lower odds of not being prescribed anticholinesterase inhibitors. More years of education were associated http://www.selleckchem.com/products/pci-32765.html with lower odds of not being prescribed neuroleptics, hypnotics or anticholinesterase inhibitors (and it was the only statistically significant finding for this endpoint). Higher BDI was associated with lower odds of not receiving neuroleptics or hipnotics. A higher MMSE score was associated with lower odds of being prescribed an anticholinesterase inhibitor. The associations between insurance status and pharmacologic treatment for depression in a clinic in Buenos Aires were investigated. To our knowledge, this is the one of the first reports about this topic in South America.